PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|May 23, 2016
Sanofi Makes Changes to Executive Committee
Author(s)Pharmaceutical Technology Editors
Sanofi announced that it is making several changes to its executive committee, effective June 1, 2016.
Advertisement
On May 23, 2016, Oliver Brandicourt, MD, CEO of Sanofi,
- Olivier Charmeil, executive vice-president and general manager, General Medicines and Emerging Markets
- Jérôme Contamine, executive vice-president, Finance
- Peter Guenter, executive vice-president and general manager, Diabetes & Cardiovascular
- Carsten Hellmann, executive vice-president and general manager of Merial (until Dec. 31, 2016)
- Karen Linehan, executive vice-president, Legal Affairs and General Counsel
- David Loew, executive vice-president and general manager of Sanofi Pasteur
- Philippe Luscan, executive vice-president, Global Industrial Affairs
- Muzammil Mansuri, PhD, executive vice-president, Strategy & Business Development
- David Meeker, MD, executive vice-president and general manager of Sanofi Genzyme
- Ameet Nathwani, MD, executive vice-president, Medical Affairs
- Roberto Pucci, executive vice-president, Human Resources
- Elias Zerhouni, MD, president, Global Research & Development.
Sanofi also announced that Suresh Kumar, executive vice-president, external affairs will be returning to the United States. He will represent the company’s interests in the US until the end of the year. Oliver Brandicourt will serve as acting head of External Affairs until a replacement for Kumar is found. Two other Sanofi executives will also be leaving the company: Pascale Witz, executive vice-president, Diabetes & Cardiovascular, and Carsten Hellmann, executive vice-president, Merial.
Sanofi also said it plans to name an executive vice-president, Consumer Healthcare (CHC) who will be a member of the Executive Committee. This person will lead a newly created CHC global business unit, which will be formed following the anticipated completion of the business swap announced in December 2015 that consists of Sanofi’s animal health business Merial and Boehringer Ingelheim’s consumer healthcare business.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement